20 Participants Needed

Accelerated TMS for Schizophrenia

(ATP Trial)

RO
AB
Overseen ByAdam Beermann, MA
Age: 18+
Sex: Any
Trial Phase: Phase 1 & 2
Sponsor: Beth Israel Deaconess Medical Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

This study is to determine the tolerability and efficacy of an accelerated schedule of Transcranial Magnetic Stimulation for treating symptoms of psychotic disorders such as schizophrenia.

Research Team

RO

Roscoe O Brady, MD, PhD

Principal Investigator

Beth Israel Deaconess Medical Center

Eligibility Criteria

This trial is for adults aged 18-65 with a diagnosis of schizophrenia, schizoaffective disorder, or at high risk for psychosis. Participants must be stable outpatients, fluent in English, and capable of completing study procedures without recent hospitalizations or medication changes.

Inclusion Criteria

I am able to complete all study-related procedures.
Must be able to read, speak, and understand English
I have been diagnosed with schizophrenia or schizoaffective disorder, or I am at high risk for developing a psychotic disorder.
See 1 more

Exclusion Criteria

I don't have conditions that increase risks from rTMS or MRI.
I have had a head injury that caused me to lose consciousness for a long time or left me with lasting neurological issues.
I have had fainting spells that might be seizures.
See 10 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive accelerated TMS sessions multiple times per day over 5 days

1 week
Multiple sessions per day

Follow-up

Participants are monitored for safety and effectiveness after treatment

24 weeks
Assessments at 1 week, 3 weeks, and 24 weeks post-treatment

Treatment Details

Interventions

  • repetitive Transcranial Magnetic Stimulation (rTMS)
Trial Overview The trial tests the safety and effectiveness of an accelerated schedule of repetitive Transcranial Magnetic Stimulation (rTMS) to treat symptoms associated with psychotic disorders like schizophrenia.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: repetitive Transcranial Magnetic Stimulation (rTMS)Experimental Treatment1 Intervention
repetitive Transcranial Magnetic Stimulation (rTMS) in a iTBS pattern to the cerebellum at 100% of resting motor threshold

Find a Clinic Near You

Who Is Running the Clinical Trial?

Beth Israel Deaconess Medical Center

Lead Sponsor

Trials
872
Recruited
12,930,000+